In-office endometrial ablation and clinical correlation of reduced menstrual blood loss and effects on dysmenorrhea and premenstrual symptomatology.
OBJECTIVE
To evaluate in-office Thermachoice III endometrial ablation on subsequent dysmenorrhea and premenstrual mood symptoms in relation to decreased menstrual blood loss.


METHODS
The study conducted was in a prospective cohort single group. Ablations were performed on 148 patients under parametrial block using dilute mepivacaine and oral anxiolysis for a diagnosis of menorrhagia. The primary endpoint was eumenorrhea or less, with secondary endpoints of dysmenorrhea reduction and premenstrual symptom alleviation. Patients were evaluated at 3 and 6 months postprocedure. Of 148 patients, 134 (90.5%) complied with follow-up.


RESULTS
At 3 months, 52% were amenorrheic; 48% reporting hypomenorrhea. Results persisted at 6 months, with 50% and 48%, respectfully. Of 134 patients, 3 were considered nonresponders at 6 months. Mean hemoglobin values increased for all groups at each time endpoint. Of 115 patients, 79 reported baseline dysmenorrhea, with improvement in visual analog scale findings at both 3 and 6 months (p<0.005). Premenstrual mood symptoms of agitation, irritability and depression also improved at both 3 and 6 months.


CONCLUSIONS
In-office Thermachoice III endometrial ablation results in decreased dysmenorrhea and improved mood in relation to decreased menstrual blood loss.
Chapa
Hector O
HO
Women's Specialty Center, 1135 North Bishop Avenue, Dallas, TX 75208, USA. chapamd@aol.com
Venegas
Gonzalo
G
Antonetti
Alfred G
AG
Van Duyne
Charles P
CP
Sandate
Jeffrey
J
Bakker
Ken
K
D000328:Adult; D000556:Ambulatory Surgical Procedures; D000772:Anesthesia, Local; D000779:Anesthetics, Local / Q000008:administration & dosage; D014151:Anti-Anxiety Agents / Q000008:administration & dosage; D015331:Cohort Studies; D004412:Dysmenorrhea / Q000601:surgery*; D055356:Endometrial Ablation Techniques; D005260:Female; D006801:Humans; D008595:Menorrhagia / Q000601:surgery*; D008619:Mepivacaine / Q000008:administration & dosage; D008875:Middle Aged; D011293:Premenstrual Syndrome / Q000601:surgery*; D011446:Prospective Studies; D012008:Recurrence; D016896:Treatment Outcome
D000779:Anesthetics, Local; D014151:Anti-Anxiety Agents; D008619:Mepivacaine